中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.015 seconds)

    Non-lethal conditioning methods for the treatment of acquired immunodeficiency syndrome
    1.
    发明授权
    Non-lethal conditioning methods for the treatment of acquired immunodeficiency syndrome 失效
    用于治疗获得性免疫缺陷综合征的非致死性调理方法

    公开(公告)号：US6039684A

    公开(公告)日：2000-03-21

    申请号：US988832

    申请日：1997-12-11

    Applicant: Suzanne T. Ildstad ,  Olav B. Bergheim

    Inventor： Suzanne T. Ildstad ,  Olav B. Bergheim

    IPC: A61K38/00 ,  A61K41/00 ,  A61P31/18 ,  C07K16/28 ,  A61N5/00

    CPC classification number: C07K16/28 ,  A61K41/00 ,  A61K38/00

    Abstract: The present invention relates to the use of a non-lethal preparative regimen for the treatment of a patient with human immunodeficiency virus (HIV) disease. In a clinical trial, an HIV-positive patient was conditioned by non-lethal doses of irradiation and a chemotherapeutic drug prior to receiving donor bone marrow cells from a baboon. While long-term engraftment of donor cells was not observed, the non-lethal preparative conditioning regimen was able to reduce the viral burden and improved the clinical outcome. Such method is useful for treatment of patients with advanced acquired immunodeficiency syndrome (AIDS).

    Abstract translation: 本发明涉及非致死性制备方案用于治疗患有人类免疫缺陷病毒（HIV）疾病的患者的用途。 在临床试验中，在接受来自狒狒的供体骨髓细胞之前，HIV阳性患者由非致死剂量的照射和化学治疗药物调理。 虽然未观察到供体细胞的长期植入，但非致死性制备性调理方案能够减少病毒负担并改善临床结果。 这种方法可用于治疗晚期获得性免疫缺陷综合征（AIDS）患者。

    Methods for the Treatment of Autoimmune Diseases
    2.
    发明申请
    Methods for the Treatment of Autoimmune Diseases 审中-公开
    自身免疫性疾病的治疗方法

    公开(公告)号：US20080194474A1

    公开(公告)日：2008-08-14

    申请号：US11569116

    申请日：2005-05-13

    Applicant: Suzanne T. Ildstad

    Inventor： Suzanne T. Ildstad

    IPC: A61K38/18 ,  C12Q1/02 ,  A61P37/00

    CPC classification number: G01N33/6872 ,  A61K38/18 ,  G01N33/5073 ,  G01N33/564 ,  G01N33/56972 ,  G01N2500/00 ,  G01N2800/042 ,  G01N2800/24

    Abstract: The invention provides for methods for causing myeloid precursor cells in bone marrow to differentiate into dendritic cells, methods of screening for compounds that relieve a block in the development of mature myeloid progeny and/or that increase the population of HSA+/Ly6C+ cells in bone marrow, and methods of preventing or delaying an autoimmune disease such as diabetes.

    Abstract translation: 本发明提供了用于使骨髓中的骨髓前体细胞分化成树突状细胞的方法，筛选减轻成熟骨髓后代发育中的阻断和/或增加HSA的总数的化合物的方法， SUP / Ly6C 细胞，以及预防或延缓自身免疫疾病如糖尿病的方法。

    Methods of screening for compounds that improve engraftment
    3.
    发明授权
    Methods of screening for compounds that improve engraftment 有权
    筛选改善植入物的化合物的方法

    公开(公告)号：US07429376B2

    公开(公告)日：2008-09-30

    申请号：US11253296

    申请日：2005-10-17

    Applicant: Suzanne T. Ildstad

    Inventor： Suzanne T. Ildstad

    IPC: A61K48/00 ,  C12N5/08 ,  C12P19/34

    CPC classification number: G01N33/5044 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2500/00

    Abstract: The invention provides for methods of screening for compounds that increase the expression of P-selectin, SDF-1, and/or CXCR4 on facilitatory cells (FCs). The invention also provides for methods of screening for compounds that increase the level of p-predendritic cells (p-pre DC) without substantially decreasing the level of natural killer (NK) cells in a population of FCs. The invention further provides for methods of characterizing the facilitating capability of FCs by evaluating such cells for the amount of P-selectin, SDF-1, and/or CXCR4.

    Abstract translation: 本发明提供了筛选在促进细胞（FC）上增加P-选择蛋白，SDF-1和/或CXCR4的表达的化合物的方法。 本发明还提供了筛选增加p-普伐他细胞（p-pre DC）水平而不显着降低FC群体中天然杀伤（NK）细胞水平的化合物的方法。 本发明还提供了通过评价这样的细胞对于P-选择蛋白，SDF-1和/或CXCR4的量来表征FC的促进能力的方法。

    Hematopoietic facilitatory cells and their uses
    4.
    发明授权
    Hematopoietic facilitatory cells and their uses 失效
    造血辅助细胞及其用途

    公开(公告)号：US5772994A

    公开(公告)日：1998-06-30

    申请号：US463908

    申请日：1995-06-05

    Applicant: Suzanne T. Ildstad ,  Richard L. Simmons ,  Camillo Ricordi ,  Sherry M. Wren ,  Christina Kaufman

    Inventor： Suzanne T. Ildstad ,  Richard L. Simmons ,  Camillo Ricordi ,  Sherry M. Wren ,  Christina Kaufman

    IPC: A61K35/12 ,  C12N5/078 ,  A01N63/00 ,  C12N15/00

    CPC classification number: C12N5/0634 ,  A61K2035/122 ,  A61K2035/124

    Abstract: The present invention relates to mammalian hematopoietic facilitatory cells (FC). In particular, it relates to the isolation, characterization and uses of the FC. The FC of the present invention can be distinguished from all other known bone marrow cells by their morphology, cell surface phenotype and in vivo function. It has now been established that purified hematopoietic stem cells alone or bone marrow cells depleted of FC do not readily engraft in a recipient. When co-administered with other bone marrow cells, especially the hematopoietic stem cells into a recipient, the FC enhance their engraftment, without apparent adverse biologic activities. In fact, the ability of the FC to enhance the engraftment of bone marrow cells in esablishing lymphohematopoietic chimerism without producing graft versus host disease also induces donor-specific tolerance to permit the permanent acceptance of donor's cells, tissues and organs. Therefore, FC may have a wide range of applications, including, but not limited to, hematopoietic reconstitution by bone marrow transplantation for the treatment of cancers, anemias, autoimmunity, immunodeficiency, viral infections and metabolic disorders as well as facilitation of solid organ, tissue and cellular transplantation.

    Abstract translation: 本发明涉及哺乳动物造血辅助细胞（FC）。 特别地，它涉及FC的隔离，表征和使用。 本发明的FC可以通过其形态，细胞表面表型和体内功能与所有其他已知的骨髓细胞区分开来。 现在已经确定，单独的纯化的造血干细胞或FC耗尽的骨髓细胞不容易在接受者中移植。 当与其他骨髓细胞，特别是造血干细胞共同施用到​​受体中时，FC增强其植入，而没有明显的不利生物活性。 事实上，FC增强骨髓细胞植入淋巴造血嵌合体而不产生移植物抗宿主病的能力也会诱发供体特异性耐受，从而允许永久接受供者的细胞，组织和器官。 因此，FC可以具有广泛的应用，包括但不限于骨髓移植造血重建用于治疗癌症，贫血，自身免疫，免疫缺陷，病毒感染和代谢紊乱以及促进实体器官组织 和细胞移植。

    Non-lethal methods for conditioning a recipient for bone marrow transplantation
    5.
    发明授权
    Non-lethal methods for conditioning a recipient for bone marrow transplantation 失效
    用于调节骨髓移植受体的非致死方法

    公开(公告)号：US5635156A

    公开(公告)日：1997-06-03

    申请号：US337785

    申请日：1994-11-14

    Applicant: Suzanne T. Ildstad

    Inventor： Suzanne T. Ildstad

    IPC: A61K41/00 ,  A61K47/48 ,  A61K51/00 ,  A61K31/00 ,  A61N5/00

    CPC classification number: A61K47/48384 ,  A61K41/00 ,  A61K47/48369

    Abstract: The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation cell type-specific antibodies, especially antibodies directed to bone marrow stromal cell markers, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.

    Abstract translation: 本发明涉及调节骨髓移植受体的非致死方法。 特别地，本发明涉及使用非致死剂量的全身照射，总淋巴样照射细胞型特异性抗体，特别是针对骨髓基质细胞标志物，细胞毒性药物或其组合的抗体。 本发明的方法具有广泛的应用，包括但不限于通过骨髓移植造血重建用于治疗血液恶性肿瘤，血液病，自身免疫，感染性疾病如获得性免疫缺陷综合征 ，以及骨髓细胞的移植以诱导对实体器官，组织和细胞移植的耐受性。

    Non-lethal methods for conditioning a recipient for bone marrow transplantation
    7.
    发明授权
    Non-lethal methods for conditioning a recipient for bone marrow transplantation 失效
    用于调节骨髓移植受体的非致死方法

    公开(公告)号：US5876692A

    公开(公告)日：1999-03-02

    申请号：US785070

    申请日：1997-01-17

    Applicant: Suzanne T. Ildstad

    Inventor： Suzanne T. Ildstad

    IPC: A61K41/00 ,  A61K47/48 ,  A61K51/10 ,  A61K31/00 ,  A61K51/00 ,  A61N5/00

    CPC classification number: A61K47/48384 ,  A61K41/00 ,  A61K47/48369

    Abstract: The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation cell type-specific antibodies, especially antibodies directed to bone marrow stromal cell markers, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.

    Abstract translation: 本发明涉及调节骨髓移植受体的非致死方法。 特别地，本发明涉及使用非致死剂量的全身照射，总淋巴样照射细胞型特异性抗体，特别是针对骨髓基质细胞标志物，细胞毒性药物或其组合的抗体。 本发明的方法具有广泛的应用，包括但不限于通过骨髓移植造血重建用于治疗血液恶性肿瘤，血液病，自身免疫，感染性疾病如获得性免疫缺陷综合征 ，以及骨髓细胞的移植以诱导对实体器官，组织和细胞移植的耐受性。

Patent Agency Ranking